Raymond James lowered the firm’s price target on Bausch + Lomb (BLCO) to $22 from $23 and keeps an Outperform rating on the shares. Bausch + Lomb reported a “solid” Q4, with Surgical and Vision Care outperforming, while Pharma missed slightly, the analyst tells investors in a research note. The guidance seems reasonable overall and should be very achievable, if not beatable, the firm contends.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- Bausch + Lomb price target lowered to $17 from $18 at BofA
- Bausch + Lomb Corporation: Sell Rating Due to Limited Growth Prospects and Strategic Challenges
- Bausch + Lomb Reports Growth Amidst Revenue Challenges
- Bausch + Lomb price target lowered to $17 from $18 at JPMorgan
- Bausch + Lomb price target lowered to $17 from $18 at Stifel